|
|
Article: MIV Therapeutics and University of British Columbia Complete Agreements for Commercialization of Proprietary Stent Coating Technology.
- Article from:
- PR Newswire
- Article date:
- March 6, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MIV Therapeutics Inc. (MIVT:OTCBB) and The University of British Columbia (UBC) are pleased to announce the completion of two license agreements which has facilitated the transfer of the HAp coating technology to MIV Therapeutics research and manufacturing facility for commercial development. The HAp coating was discovered at UBC and has been co- developed by MIVT and UBC under a Collaborative Research Agreement.
"The transfer of the HAp technology to MIVT's manufacturing facility enables our engineering staff to optimize the process controlled parameters determining the uniformity, consistency, producibility and porosity of the HAp coating. In-house development ...